NIH

President Biden has finalized deals to buy 200 million more COVID-19 vaccine doses from Pfizer and Moderna by the end of July, increasing the likelihood of delivering on his promise to have all Americans inoculated by mid-summer.

Monoclonal antibody drugs are supposed to help people with mild to moderate COVID-19 avoid the hospital, but it can be a challenge to find out where the treatment is offered. NPR has heard from people across the country who have been frustrated by this. They include Shirley Wagoner, an 80-year-old who still hits the ski slopes and helps run the family plumbing business in Spokane Valley, Wash.

The NIH said that while the anti-malarial drug did not cause harm to patients in the study, testing showed little evidence that it would benefit patients hospitalized with COVID-19.

Richard Bright says he was removed from his post because of his "insistence" that the government spend funds on "safe and scientifically vetted solutions" to address the coronavirus.